the role of molecular genetic alterations in sensitivity of the adjuvant intravesical therapy for non-muscle invasive bladder cancer [Роль...
Михайленко Д. С., Сергиенко С. А., Заборскy И. Н., Сафиуллин К. Н., Серебрянy С. А., Сафронова Н. Y., Немцова М. В., Каприн А. Д., Алексеев Б. Y.
Онкоурология
Т. 14, Вып. 4, С. 124-138
Опубликовано: 2018
Тип ресурса: Статья
DOI:10.17650/1726-9776-2018-14-4-124-138
Аннотация:
Bladder cancer (BC) is represented by non-muscle-invasive forms at the stage Ta, T1, CIS (NMBC) in 75 [%] of cases. The gold standard of treatment of NMBC patients is transurethral resection, but its implementation does not always allow the patient to be relieved of the recurrence of the disease. In this regard, patients with a low risk of progression after transurethral resection are administered by intravesical chemotherapy, with high risk (T1G2/3) – using instillation with BCG (Bacillus Calmette–Guerin) vaccine. Searching of NMBC markers for laboratory diagnostics, which would help to determine sensitivity or resistance to the planned type of adjuvant therapy remains an actual problem. The data published mainly in the last 5–7 years about genetic predictors of the response to adjuvant chemotherapy and, to a greater extent, immunotherapy with BCG vaccine, are reviewed in this work. Allele combinations in the genes involved in immune response, xenobiotic biotransformation and other loci
Ключевые слова:
BCG therapy; Bladder cancer; Gene expression; Genetic polymorphism; Immunotherapy; Microsatellite instability; Mutational load; Somatic mutation
Язык текста: Русский
ISSN: 1996-1812
Михайленко Д. С. Дмитрий Сергеевич 1981-
Сергиенко С. А.
Заборскy И. Н.
Сафиуллин К. Н.
Серебрянy С. А.
Сафронова Н. Y. Н.Ю.
Немцова М. В. Марина Вячеславовна 1962-
Каприн А. Д.
Алексеев Б. Y. Б.Я.
Mikhaylenko D. S. Dmitrij Sergeevich 1981-
Sergienko S. A.
Zaborsky I. N.
Safiullin K. N.
Serebryany S. A.
Safronova N. Y. N.Yu.
Nemtsova M. V. Marina Vyacheslavovna 1962-
Kaprin A. D.
Alekseev B. Y. B.Ya.
the role of molecular genetic alterations in sensitivity of the adjuvant intravesical therapy for non-muscle invasive bladder cancer [Роль молекулярно-генетических изменений в прогнозе эффективности адъювантной внутрипузырной терапии немышечно-инвазивного рака мочевого пузыря]
the role of molecular genetic alterations in sensitivity of the adjuvant intravesical therapy for non-muscle invasive bladder cancer [Роль...
Текст визуальный непосредственный
Онкоурология
Издательский дом "АБВ-пресс"
Т. 14, Вып. 4 С. 124-138
2018
Статья
BCG therapy Bladder cancer Gene expression Genetic polymorphism Immunotherapy Microsatellite instability Mutational load Somatic mutation
Bladder cancer (BC) is represented by non-muscle-invasive forms at the stage Ta, T1, CIS (NMBC) in 75 [%] of cases. The gold standard of treatment of NMBC patients is transurethral resection, but its implementation does not always allow the patient to be relieved of the recurrence of the disease. In this regard, patients with a low risk of progression after transurethral resection are administered by intravesical chemotherapy, with high risk (T1G2/3) – using instillation with BCG (Bacillus Calmette–Guerin) vaccine. Searching of NMBC markers for laboratory diagnostics, which would help to determine sensitivity or resistance to the planned type of adjuvant therapy remains an actual problem. The data published mainly in the last 5–7 years about genetic predictors of the response to adjuvant chemotherapy and, to a greater extent, immunotherapy with BCG vaccine, are reviewed in this work. Allele combinations in the genes involved in immune response, xenobiotic biotransformation and other loci